Xanthine Oxidase Activity in Type 2 Diabetes Mellitus Patients with and without Diabetic Peripheral Neuropathy

Journal of Diabetes Research

Volumn 2016, Issue , 2016, Pages

  Miric, Dijana J ^a   Kisic, Bojana M ^a   Filipovic Danic, Snezana ^a   Grbic, Rade ^a   Dragojevic, Ilija ^a   Miric, Marko B ^a   Puhalo Sladoje, Dragana ^b  

^a UNIVERSITY OF PRI TINA   (Serbia)

^b UNIVERSITY OF EAST SARAJEVO   (Bosnia and Herzegovina)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALBUMIN; HEMOGLOBIN A1C; INSULIN; ISCHEMIA MODIFIED ALBUMIN; ORAL ANTIDIABETIC AGENT; THIOL; XANTHINE OXIDASE; BIOLOGICAL MARKER; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; ISCHEMIA-MODIFIED ALBUMIN; SERUM ALBUMIN; THIOL DERIVATIVE; URIC ACID;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES MELLITUS; DIABETIC NEUROPATHY; DIABETIC PATIENT; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MIDDLE AGED; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL NEUROPATHY; RISK FACTOR; AGED; CASE CONTROL STUDY; COMPLICATION; DIABETIC NEUROPATHIES; METABOLISM; MULTIVARIATE ANALYSIS; STATISTICAL MODEL; TIME FACTOR;

AGED; BIOMARKERS; BODY MASS INDEX; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERTENSION; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; SERUM ALBUMIN; SULFHYDRYL COMPOUNDS; TIME FACTORS; URIC ACID; XANTHINE OXIDASE;

EID: 84999622261     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2016/4370490     Document Type: Article

References (38)

1. Z. Vukojevíc, T. Pekmezovíc, A. Nikolíc et al., "Correlation of clinical and neurophysiological findings with health related quality of life in patients with diabetic polyneuropathy, "Vojnosanitetski Pregled, vol. 71, no. 9, pp. 833-838, 2014.
2. Y. Mochizuki, H. Tanaka, K. Matsumoto et al., "Association of peripheral nerve conduction in diabetic neuropathy with subclinical left ventricular systolic dysfunction, "Cardiovascular Diabetology, vol. 14, no. 1, article 47, 2015.
3. S. Tesfaye, "Epidemiology and etiology of diabetic peripheral neuropathies, "Advanced Studies in Medicine, vol. 4, no. 10 G, pp. S1014-S1021, 2004.
4. R. Singh, L. Kishore, and N. Kaur, "Diabetic peripheral neuropathy: current perspective and future directions, "Pharmacological Research, vol. 80, pp. 21-35, 2014.
5. I. G. Obrosova, J. G. Mabley, Z. Zsengellér et al., "Role for nitrosative stress in diabetic neuropathy: evidence from studies with a peroxynitrite decomposition catalyst, "FASEB Journal, vol. 19, no. 3, pp. 401-403, 2005.
6. M.-C. Desco, M. Asensi, R. Márquez et al., "Xanthine oxidase is involved in free radical production in type 1 diabetes: protection by allopurinol, "Diabetes, vol. 51, no. 4, pp. 1118-1124, 2002.
7. U. R. Kuppusamy, M. Indran, and P. Rokiah, "Glycaemic control in relation to xanthine oxidase and antioxidant indices in Malaysian Type 2 diabetes patients, "Diabetic Medicine, vol. 22, no. 10, pp. 1343-1346, 2005.
8. D. J. Miric, B. B. Kisic, L. D. Zoric, R. V. Mitic, B. M. Miric, and I. M. Dragojevic, "Xanthine oxidase and lens oxidative stress markers in diabetic and senile cataract patients, "Journal of Diabetes and Its Complications, vol. 27, no. 2, pp. 171-176, 2013.
9. A. M. P. Feoli, F. E. Macagnan, C. H. Piovesan, L. C. Bodanese, and I. R. Siqueira, "Xanthine Oxidase activity is associated with risk factors for cardiovascular disease and inflammatory and oxidative status markers in metabolic syndrome: effects of a single exercise session, "Oxidative Medicine and Cellular Longevity, vol. 2014, Article ID 587083, 8 pages, 2014.
10. M. E. Inkster, M. A. Cotter, and N. E. Cameron, "Treatment with the xanthine oxidase inhibitor, allopurinol, improves nerve and vascular function in diabetic rats, "European Journal of Pharmacology, vol. 561, no. 1-3, pp. 63-71, 2007.
11. N. Papanas, N. Katsiki, K. Papatheodorou et al., "Peripheral neuropathy is associated with increased serumlevels of uric acid in type 2 diabetesmellitus, "Angiology, vol. 62, no. 4, pp. 291-295, 2011.
12. D. Bar-Or, E. L. Lau, and J. V. Winkler, "Anovel assay for cobaltalbumin binding and its potential as a marker for myocardial ischemia-a preliminary report, "Journal of Emergency Medicine, vol. 19, no. 4, pp. 311-315, 2000.
13. K. Ukinc, S. Eminagaoglu, H. O. Ersoz et al., "A novel indicator of widespread endothelial damage and ischemia in diabetic patients: ischemia-modified albumin, "Endocrine, vol. 36, no. 3, pp. 425-432, 2009.
14. S.-G. Ma, C.-L. Wei, B. Hong, and W.-N. Yu, "Ischemiamodified albumin in type 2 diabetic patients with and without peripheral arterial disease, "Clinics, vol. 66, no. 10, pp. 1677-1680, 2011.
15. J. W. G. Meijer, A. J. Smit, E. V. Sonderen, J. W. Groothoff, W. H. Eisma, and T. P. Links, "Symptom scoring systems to diagnose distal polyneuropathy in diabetes: the diabetic neuropathy symptom score, "Diabetic Medicine, vol. 19, no. 11, pp. 962-965, 2002.
16. E. L. Feldman, M. J. Stevens, P. K. Thomas, M. B. Brown, N. Canal, and D. A. Greene, "A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy, "Diabetes Care, vol. 17, no. 11, pp. 1281-1289, 1994.
17. K. V. Lemley, I. Abdullah, B. D. Myers et al., "Evolution of incipient nephropathy in type 2 diabetes mellitus, "Kidney International, vol. 58, pp. 1228-1237, 2000.
18. G. G. Roussos, "Xanthine oxidase from bovine small intestine, "Methods in Enzymology, vol. 12, pp. 5-16, 1967.
19. E. Beutler, O. Duron, andB. M. Kelly, "Improvedmethodfor the determination of blood glutathione, "The Journal of Laboratory and Clinical Medicine, vol. 61, pp. 882-888, 1963.
20. M. Kalousová, J. Skrha, and T. Zima, "Advanced glycation endproducts and advanced oxidation protein products in patients with diabetes mellitus, "Physiological Research, vol. 51, no. 6, pp. 597-604, 2002.
21. B. Anderstam, B.-H. Ann-Christin, A. Valli, P. Stenvinkel, B. Lindholm, and M. E. Suliman, "Modification of oxidative stress biomarker AOPP assay: application in uremic samples, "Clinica Chimica Acta, vol. 393, no. 2, pp. 114-118, 2008.
22. M. Dobiásová and J. Frohlich, "The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate inapob-lipoproteindepleted plasma (FERHDL), "Clinical Biochemistry, vol. 34, no. 7, pp. 583-588, 2001.
23. A. M. Vincent, J. W. Russell, P. Low, and E. L. Feldman, "Oxidative stress in the pathogenesis of diabetic neuropathy, "Endocrine Reviews, vol. 25, no. 4, pp. 612-628, 2004.
24. A. C. P. Oliveira, C. J. Teixeira, T. F. Stefanello et al., "Oxidative stress parameters as biomarkers of risk factor for diabetic foot among the patients with type 2 diabetes, "Brazilian Archives of Biology and Technology, vol. 57, no. 2, pp. 223-227, 2014.
25. A. Altuntas, S. S. Goksu, V. Kidir, Z. D. Aydin, and M. T. Sezer, "Uric acid levels are inversely correlated with endothelial function in type 2 diabetic patients, "International Journal of Clinical and ExperimentalMedicine, vol. 9, pp. 14105-14113, 2016.
26. R. Wada and S. Yagihashi, "Role of advanced glycation end products and their receptors in development of diabetic neuropathy, "Annals of the New York Academy of Sciences, vol. 1043, pp. 598-604, 2005.
27. D. Bansal, K. Gudala, H. Muthyala, H. P. Esam, R. Nayakallu, and A. Bhansali, "Prevalence and risk factors of development of peripheral diabetic neuropathy in type 2 diabetes mellitus in a tertiary care setting, "Journal of Diabetes Investigation, vol. 5, no. 6, pp. 714-721, 2014.
28. K. J. Cheung, I. Tzameli, P. Pissios et al., "Xanthine oxidoreductase is a regulator of adipogenesis and PPAR activity, "Cell Metabolism, vol. 5, no. 2, pp. 115-128, 2007.
29. Y. Tsushima, H. Nishizawa, Y. Tochino et al., "Uric acid secretion fromadipose tissue andits increase inobesity, "Journal of Biological Chemistry, vol. 288, no. 38, pp. 27138-27149, 2013.
30. G. H. Tesch, "Role of macrophages in complications of Type 2 diabetes, "Clinical and Experimental Pharmacology and Physiology, vol. 34, no. 10, pp. 1016-1019, 2007.
31. N.-H. Kim, S. Choi, E.-J. Han et al., "The xanthine oxidase-NFAT5 pathway regulates macrophage activation and TLRinduced inflammatory arthritis, "European Journal of Immunology, vol. 44, no. 9, pp. 2721-2736, 2014.
32. A. Ives, J. Nomura, F. Martinon et al., "Xanthine oxidoreductase regulates macrophage IL1 secretion upon NLRP3 inflammasome activation, "Nature Communications, vol. 6, article 6555, 2015.
33. J. A. Honorat, M. Kinoshita, T. Okuno et al., "Xanthine oxidase mediates axonal and myelin loss in a murine model of multiple sclerosis, "PLoS ONE, vol. 8, no. 8, Article ID e71329, 2013.
34. H. M. El-Bassossy and M. L. Watson, "Xanthine oxidase inhibition alleviates the cardiac complications of insulin resistance: effect on low grade inflammation and the angiotensin system, "Journal of Translational Medicine, vol. 13, article 82, 2015.
35. R. Butler, A. D. Morris, J. J. F. Belch, A. Hill, and A. D. Struthers, "Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension, "Hypertension, vol. 35, no. 3, pp. 746-751, 2000.
36. J. George and A. D. Struthers, "Role of urate, xanthine oxidase and the effects of allopurinol in vascular oxidative stress, "VascularHealth and RiskManagement, vol. 5, pp. 265-272, 2009.
37. M. Connor, "Allopurinol for pain relief: more than just crystal clearance?"British Journal of Pharmacology, vol. 156, no. 1, pp. 4-6, 2009.
38. R. Pop-Busui, M. J. Stevens, D. M. Raffel et al., "Effects of triple antioxidant therapy on measures of cardiovascular autonomic neuropathy and on myocardial blood flow in type 1 diabetes: a randomised controlled trial, "Diabetologia, vol. 56, no. 8, pp. 1835-1844, 2013.